DV
Dividend Vision

BNR — Burning Rock Biotech Ltd

Burning Rock Biotech Ltd (BNR)

Total return is -96.4% over the past 6.2 years, 274.7 points behind SPY at 178.3%. Its deepest 1-year drawdown was 82.9%.

Burning Rock Biotech Limited develops and commercializes cancer therapy selection tests based on next-generation sequencing technology, operating through central laboratory services, in-hospital testing, and pharma research divisions across China and the United States. The company does not currently distribute dividends. The business appeals to growth-oriented investors focused on the oncology diagnostics and precision medicine sector.

BNR key facts

Asset type
Stock
Asset class
Equity
Inception date
06/12/2020
Last close
$8.83
Market cap
$105,147,040
Average volume
16097.0
Beta
1.332
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.82